Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, dose escalation study of patients with
alpha-mannosidosis. 10 patients will be enrolled in this study receiving intravenous
infusions of Lamazym. In order to avoid development of delayed hypersensitivity all patients
will continue weekly treatment at the designated dose until the Safety Committee approves
transfer to the rhLAMAN-03 protocol.
It is the hypothesis that Lamazym is safe to use.